• Recruiting

NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+

Updated: May 23

NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


Descartes 08

NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.


Sponsor

Cartesian Therapeutics

 

ClinicalTrials.gov Identifier: NCT04816526


Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy


First Posted : March 25, 2021


Click here for details on ClinicalTrials.gov

 

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes

anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells

autologous anti-BCMA-CAR-mRNA-transfected CD8-positive T cells

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T cells

Descartes-08


Cartesian Therapeutics

 

Biological:

Descartes 08

Car T-cells

 

CA: University of California Irvine

Orange, California, United States, 92868

TN: Sarah Cannon Research Institute at Tennessee Oncology

 

Locations

United States, California

United States, Tennessee






Posts Archive